Conavi Medical

Disrupting #ImageFirst with Novasight Hybrid, the first intracoronary imaging system combining co-registered #IVUS and #OCT
$CNVI.V $CNVIF

[Conavi Medical @ConaviMed]

New @MyJSCAI publication analyzed 25 studies across multiple countries...

When evaluated over a patient’s lifetime, #IntravascularImaging not only improves outcomes significantly, but is cost-effective and often cost-saving, reducing adverse events and repeat interventions.

Increases number of #PCI procedures, clinical evidence, guideline support, and adoption of IVI, understanding its long-term economic impact has become increasingly important.

Read more on the publication here 🔗 https://t.co/wMXlEiQSNp

$CNVI.V $CNVIF @SCAI #Conavi

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

From CEO @ThomasLooby:

"Fiscal Q2 2026 marked a transformational period for #Conavi highlighted by FDA #510k clearance of our next-generation hybrid #IVUS-#OCT imaging system, a milestone that positions the Company for commercial launch in the U.S..."

Read more 🔗 https://t.co/Gj7QzXy6ki

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

#Conavi CEO @ThomasLooby sat down with @RadiusResearch to discuss everything surrounding our next-generation imaging system and recent U.S. #FDA 510(k) clearance! ☑️

Watch the full video here 🔗 https://t.co/n1YeXurce1

#CNVI #IntravascularImaging #510k #CEOInterview

[Martin Gagel @RadiusResearch]

📋 @ConaviMed (TSXV: $CNVI | OTCQB: $CNVIF) – FDA Clearance Update

CEO Thomas Looby reviews the recent FDA clearance of #ConaviMedicals's next-generation hybrid #intravascularimaging system and discusses what the milestone means for the company's position in the #cardiovascularimaging market.

▶️ Watch the full interview here ➝ https://t.co/7Q6p8DHo8h

#MedTech #MedicalDevices #HealthcareInnovation

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

▶️ In case you missed it: #TBT to the #BBHIC2026 last week!

1st #Conavi presentation after receiving U.S. FDA #510k clearance on our next-generation hybrid imaging system.

🔗 Watch it here: https://t.co/wqYS8B1xCT

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF Exciting week! 🫀

☑️U.S. FDA #510k Clearance ☑️ Productive time at #BBHIC2026 ☑️#TagAward Recipient

🔗 https://t.co/QEFxX5zGsk

As #Conavi CEO Tom Looby expressed:

"We are honoured to receive this recognition from TAG at such an important moment for Conavi, this award reflects the strength of our technology and the dedication of our team. With the recent FDA clearance of our next-generation hybrid intravascular imaging system, we are entering a new phase focused on U.S. commercialization and delivering meaningful clinical impact."

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

#Conavi is thrilled to announce FDA #510k clearance of our next-generation hybrid imaging system and to begin executing on our U.S. commercial launch for H2 2026.

As the first co-registered, co-aligned #IVUS and #OCT platform, our system helps give physicians a more complete view of the vessel, streamline workflows, and enhance precision across one of the most common procedures globally.

With clinical evidence and guideline support strengthening, this represents a significant opportunity in the rapidly expanding #IntravascularImaging market.

Thank you to the #CNVI team, partners, physicians, and investors who made this possible! 🫀🌏

Full Release 🔗 https://t.co/dXVOvkAKjl

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

CEO @ThomasLooby will be presenting and available for 1-on-1 meetings at the the 2026 Bloom Burton & Co. Healthcare Investor Conference.

#Conavi Presentation Details:
📆 Wednesday April 22
🕥 9:30 a.m. ET
📍 Metro Toronto Convention Centre

▶️ Webcast: https://t.co/OCxaX6Pru4
🔗 More Information: https://t.co/drKTK3Sqt8

#BBHIC26

[Conavi Medical @ConaviMed]

$CNVI $CNVIF

On #WorldHealthDay, we join @WHO to #StandWithScience! 🧡🌎

Behind the 4M+ #PCI's performed each year, is a parent, spouse, friend, and a physician turning evidence into action to save lives.

#Conavi believes powerful health decisions start with clarity and advance without compromise.

This is why we’re combining #IVUS with #OCT to remove potential blind spots with single modality #IntravascularImaging systems. 🩺

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF
It’s the season for springing into our next-gen imaging! 🌱

On the Empowered Patient Podcast, #Conavi CEO @ThomasLooby discussed how we're leveraging #AI in our #hybridimaging to drive stronger algorithms, automated insights, and less guesswork for cardiologists. 🫀

Listen here 🎧 https://t.co/leOh7AMiND

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

A @EuroInterventio analysis of 350,000+ coronary procedures in Japan’s National Database, shows how imaging-guided PCI is:

➡️ Delivering significantly better outcomes for ACS patients
➡️ Driving a fundamental shift in how interventions are performed
➡️ Demonstrating how #IVUS & #OCT reveals what the other cannot

Providing physicians with the ability to leverage strengths of both modalities during the same procedure is what #ConaviMedical feels is an important step forward in #InterventionalCardiology. 🫀

Details 🔗 https://t.co/xvHhkiVw6E

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

Another validating quarter for #Conavi!

$12M in funding secured and another publication reinforcing the advantages of hybrid #IVUS + #OCT imaging.

We’re advancing the next-generation #Novasight toward commercialization with confidence and are on track to initiate the targeted U.S. launch in Q3 2026.

Full update 🔗 https://t.co/6s73zSod2U

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

Excited to highlight a new peer-reviewed publication in Cardiovascular Research by the @escardio 🔖

Congratulations to Dr. Brian Courtney and the teams at Sunnybrook, University of Toronto, Barts Heart Centre, & Queen Mary University of London.

After a decade of collaborative #hybridimaging research, the IVUS-OCT deep-learning classifier outperformed:
✅ Human expert readers
✅ #IVUS alone
✅ #OCT alone

The findings reinforce the clinical value proposition behind #Conavi's technology platform.

🔗 https://t.co/JDQWlHiQjt

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

Every heartbeat reminds us why we do what we do at #ConaviMedical.

This #HeartMonth, we celebrate the researchers and engineers advancing cardiac care, the physicians guiding complex procedures, and the patients whose lives are shaped by better outcomes.

When your most vital organ is on the line, precision matters more than ever. 🫀

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

#Conavi closed it's $12M public offering!

Proceeds are intended to be used toward obtaining FDA #510k clearance for next-gen #Novasight, initiating a targeted market release in the U.S., and supporting general corporate activities.

Big thanks to Bloom Burton Securities and to all the U.S. strategic healthcare investors who participated.

🔗Read more: https://t.co/trhR0WwL9i

[Conavi Medical @ConaviMed]

$CNVI $CNVIF

As CEO @ThomasLooby expressed, "Fiscal 2025 was a transformational year for #Conavi as we executed across regulatory, clinical, financial, and operational milestones..."

🔗Full #FY2025 Release: https://t.co/ryBN2inW51

[Conavi Medical @ConaviMed]

$CNVI $CNVIF

Happy Holidays from all of us at #ConaviMedical! 🫶

Wishing you a meaningful season spent with family and loved ones. Thank you to everyone who's been a part of our journey, we look forward to a bright year ahead!

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

A key moment in this chat with @RadiusResearch reflects on our insights from #TCT2025!

The adoption of #IntravascularImaging is accelerating globally and is increasingly recognized as an essential tool in #PCI's, supporting physicians with enhanced visualization and informed clinical decision-making. 🫀

This captures the energy and momentum driving the next phase of #Conavi's next-gen #Novasight journey.

🔗https://t.co/mrtzqUp1gs

[Conavi Medical @ConaviMed]

$CNVI.V is at an inflection point 💥

CEO @ThomasLooby shares the key $CNVIF milestones coming together for next-gen #Novasight U.S. commercial launch activities:

☑️ FDA 510(k) submission
☑️ Leadership Expansion
☑️ $2.5m #LSSUF funding

Thanks @RadiusResearch for another great catch up chat! Watch the full #Conavi update 🔽

[Martin Gagel @RadiusResearch]

💡 @ConaviMed (TSXV: $CNVI | OTCQB: $CNVIF) Provides Business Update

CEO Tom Looby discusses the company’s latest progress, including a $2.5M funding package from the Province of Ontario to support the launch of its next-generation Novasight Hybrid™ Imaging System, advancing innovation in #cardiovascularimaging.

🎥 Watch the full update >> https://t.co/zz9QbJN8h2

#ConaviMedical #MedTech #Cardiology #MedicalDevices #Healthcare

[Conavi Medical @ConaviMed]

$CNVI.V $CNVIF

Please welcome Mark Quick to our leadership team as CFO.

With 20+ years in U.S. #medtech and #lifesciences finance, he joins #Conavi at a pivotal moment for next-gen #Novasight, helping prepare for a successful U.S. launch and expand our presence in the world’s largest #intravascularimaging market.

Thank you to Stefano Picone, who has been instrumental in Conavi’s growth over the past decade. We’re excited he’ll continue to guide our strategy and support this next phase.

🔗Full #CNVI release: https://t.co/tASEkLnXXC